Results 231 to 240 of about 73,785 (303)

Thirty Years of Autologous Platelet Concentrates: From Platelet‐Rich Plasma to Platelet‐Rich Fibrin

Journal of Periodontal Research, EarlyView.
This review highlights the 30 years of evolution of APCs, with a focus on their clinical applications and recent technological advancements. ABSTRACT Nearly three decades have now passed since autologous platelet concentrates (APCs) were introduced into clinical practice.
Richard J. Miron, Nathan E. Estrin, Paras Ahmad, Nima Farshidfar, Masako Fujioka‐Kobayashi, Yufeng Zhang, Mario Romandini, Reinhard Gruber   +7 more
wiley   +1 more source

Direct Oral Anticoagulant Use in Older Adults with Atrial Fibrillation: Challenges and Solutions. [PDF]

Eur Cardiol
Bhandari M, Pradhan A, Vishwakarma P, Di Renzo L, Iellamo F, Ali W, Perrone MA.   +6 more
europepmc   +1 more source

Soft‐Tissue Phenotype Modification as an Adjunct to the Treatment of Peri‐Implant Mucositis—A Quasi‐Randomized Clinical Trial

Journal of Periodontal Research, EarlyView.
This study showed that soft‐tissue phenotype modification provides additional benefits beyond non‐surgical therapy in managing peri‐implant mucositis. Notably, the effects on peri‐implant health were not mediated by improved plaque control. ABSTRACT Aim This quasi‐randomized clinical trial evaluated the additional benefit of soft‐tissue phenotype ...
Zeynep Aksu, Sila Cagri Isler, Berrin Unsal, Andrea Roccuzzo, Mario Romandini   +4 more
wiley   +1 more source

Direct Oral Anticoagulant-Related Bleeding in Atrial Fibrillation Patients Leads to <i>ADAMTS7</i> Promoter Demethylation. [PDF]

Genes (Basel)
Ragia G, Thomopoulos T, Pallikarou M, Atzemian N, Maslarinou A, Chalikias G, Trikas A, Tziakas DN, Manolopoulos VG.   +8 more
europepmc   +1 more source

Platelet‐Rich Fibrins as Local Drug‐Delivery Carriers

Journal of Periodontal Research, EarlyView.
Autologous platelet concentrates (APCs), particularly platelet‐rich fibrin (PRF), act as biologically active fibrin scaffolds, capable of entrapping and gradually releasing therapeutic agents in oral and periodontal therapy. The incorporation of bioactive compounds, such as antibiotics, antifungals, vitamins, antidiabetic drugs, and exosomes, enhances ...
Karim M. Fawzy El‐Sayed, Christof E. Dörfer   +1 more
wiley   +1 more source

Optimal direct oral anticoagulant for upper gastrointestinal endoscopic submucosal dissection. [PDF]

J Gastroenterol
Ono Y, Hatta W, Tarasawa K, Ogata Y, Abe H, Sato I, Hatayama Y, Saito M, Jin X, Uno K, Koike T, Imatani A, Hamada S, Fujimori K, Fushimi K, Masamune A.   +15 more
europepmc   +1 more source

Pharmacokinetics and Anti‐Inflammatory Effects of Intramuscular Betamethasone in Exercised Thoroughbred Horses

Journal of Veterinary Pharmacology and Therapeutics, EarlyView.
ABSTRACT The pharmacokinetics and pharmacodynamics of betamethasone following intra‐articular administration to horses have been described; however, studies characterizing intramuscular administration are lacking. Twenty‐four horses received an intramuscular dose of 12 mg betamethasone sodium phosphate/betamethasone acetate.
Juliana Sullivan, Jeff Blea, Daniel S. McKemie, Philip H. Kass, Heather K. Knych   +4 more
wiley   +1 more source

Clinical outcomes with the use of aspirin vs. clopidogrel as a combination therapy with direct oral anticoagulant after coronary stent implantation in patients with atrial fibrillation. [PDF]

Eur Heart J Cardiovasc Pharmacother
Kim S, Park S, Kim H, Aung N, Kim SH, Chang K, Choi Y.   +6 more
europepmc   +1 more source

Effects of Oral Single‐Dose Empagliflozin on Urinary Glucose, Serum β‐Hydroxybutyrate, and Plasma Empagliflozin Concentrations in Healthy Adult Dogs

Journal of Veterinary Pharmacology and Therapeutics, EarlyView.
ABSTRACT Empagliflozin is a sodium‐glucose cotransporter‐2 inhibitor used for treating humans with heart failure, among other conditions. This drug could have applications in veterinary cardiology, but whether empagliflozin has biological effects in dogs when administered at dosages approximating human therapeutic dosages is unknown.
Andrea D. Plá Gutierrez, M. Lynne O'Sullivan, Etienne Côté, Sandra McConkey, Butch KuKanich, Stephanie E. Martinez   +5 more
wiley   +1 more source

Plain language summary of the direct oral anticoagulant switch study: effect of switching or continuing apixaban or rivaroxaban among people with non-valvular atrial fibrillation. [PDF]

Future Cardiol
Deitelzweig S, Jiang J, Subash R, Cheng D, Lip GYH.   +4 more
europepmc   +1 more source